Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Frontline therapy patterns and outcomes in chronic lymphocytic leukemia: A real-world, multicenter analysis from Latin America.

Celso Arrais-Rodrigues, Ana Oliver, Maria Cugliari, Luis Mario Villela Martinez, Macarena Roa, Lorena Cardozo, Marialejandra Torres Viera, Denisse Castro, Daniela Trujillo Loaiza, Leila Perobelli, Anelys García Salgado, Victoria Irigoin, Sofía Rivarola, Virginia Lema Spinelli, Jose Alvarez, Alana von Glasenapp, Camila Peña, Sally Paredes, Valeria Buccheri, Gislaine Duarte, Maura Colturato, Laura Fogliatto, Ana Ines Landoni, Sabrina ranero Ferrari, Augusto Mirolli, Marta Zerga, Miguel Pavlovsky, Nancy Cristaldo, Maria Del Rosario Custidiano, Fernando Pérez-Jacobo, Danielle De Farias, Maria Orlova, Julio Pose Cabarcos, Fernando Barroso Duarte, Etelvina Macchiavello, Sérgio Fortier, Julia Laviano, Clarisa Pagano Vilar, Nelson Hamerschlak, Vera Figueiredo, Rosa Rios Jimenez, Arianna Robles, Javier Retamales, Melanie Otañez, German Stemmelin, Henry Idrobo, Brady Beltran, Jorge Castillo, Luis Malpica, Carlos Chiattone

Blood (2025) 146 (Supplement 1): 2775.

https://doi.org/10.1182/blood-2025-2775

Published: 2025

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 226.

https://doi.org/10.1182/blood-2025-226

Published: 2025

Journal Articles

High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study

Blood (2025) 146 (Supplement 1): 225.

https://doi.org/10.1182/blood-2025-225

Published: 2025

Journal Articles

Double-hit alterations of TP53 identify ultra high-risk disease in previously treated, MYD88 mutated waldenstrom macroglobulinemia.

Nickolas Tsakmaklis, Alberto Guijosa, Andres Ramirez, Amanda Kofides, Abigail Peachey, Xia Liu, Hao Sun, Maria Luisa Guerrera, Christopher Patterson, Andrew Branagan, Shayna Sarosiek, Jorge Castillo, Zachary Hunter, Steven Treon

Blood (2025) 146 (Supplement 1): 224.

https://doi.org/10.1182/blood-2025-224

Published: 2025

Journal Articles

Real-world outcomes of primary gastric diffuse large B cell lymphoma in Latin America: A multicenter cohort from the grupo de estudio latinoamericano de linfoproliferativos (GELL)

Rafael Pichardo-Rodriguez, Brady Beltran, Luis Mario Villela Martinez, Ana Oliver, Maria Alejandra Torres, Luis Felipe Rubalcava, Arianna Robles Rodriguez, Rosio Baena, Jose Macias Abasto, Melisa Castro, Rocío Ramírez, Manuel M. Vela-Ruiz, Carlos Ángulo, Jose A Hernandez-Hernandez, Henry Idrobo, Myrna Candelaria, Bryan Valcarcel, Jorge Castillo, Luis Malpica

Blood (2025) 146 (Supplement 1): 5451.

https://doi.org/10.1182/blood-2025-5451

Published: 2025

Journal Articles

Comparative effectiveness of R-minichop versus R-CHOP in older patients with diffuse large B-cell lymphoma: A propensity score-matched analysis from a real-world grupo de estudio latinoamericano de linfoproliferativos (GELL) cohort

Blood (2025) 146 (Supplement 1): 5450.

https://doi.org/10.1182/blood-2025-5450

Published: 2025

Journal Articles

Machine learning-based immunoinflammatory phenotypes predict survival in Latin American patients with diffuse large B-cell lymphoma: A multicenter cohort study of grupo de estudio latinoamericano de linfoproliferativos (GELL)

Blood (2025) 146 (Supplement 1): 5447.

https://doi.org/10.1182/blood-2025-5447

Published: 2025

Journal Articles

Deep responses following treatment with loncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those withhigh-risk, TP53-altered Waldenström macroglobulinemia.

Shayna Sarosiek, Mary Kwok, Prashant Kapoor, Hannah Chory, Nina Budano, Julia Nguyen, Alexandra Eurell, Kirsten Meid, Alberto Guijosa, Nickolas Tsakmaklis, Zachary Hunter, Andrew Branagan, Steven Treon, Jorge Castillo

Blood (2025) 146 (Supplement 1): 581.

https://doi.org/10.1182/blood-2025-581

Published: 2025

Journal Articles

Novel mechanistic insights for IRAK1 and IRAK4 signaling provide a framework for the development of dual IRAK1 and IRAK4 protacs for MYD88 mutated lymphomas.

Xia Liu, Shirong Liu, Amanda Kofides, Dominic Pizzarella, Jinhua Wang, Sara Buhrlage, Nickolas Tsakmaklis, Abigail Peachey, Alberto Guijosa, Hao Sun, Maria Luisa Guerrera, Christopher Patterson, Shayna Sarosiek, Jorge Castillo, Zachary Hunter, John Hatcher, Steven Treon

Blood (2025) 146 (Supplement 1): 5324.

https://doi.org/10.1182/blood-2025-5324

Published: 2025

Journal Articles

Prognostic factors and 5-year overall survival in older adults (≥60 years) with Hodgkin lymphoma in Latin America: A multicenter cohort study

Blood (2025) 146 (Supplement 1): 7145.

https://doi.org/10.1182/blood-2025-7145

Published: 2025

Journal Articles

Venetoclax or pirtobrutinib in relapsed/refractory Waldenström macroglobulinemia: Clinical and molecular predictors and sequencing implications

Alberto Guijosa, Nickolas Tsakmaklis, Margaret Kobs, Nina Budano, Julia Nguyen, Alexandra Eurell, Maria Luisa Guerrera, Gottfried von Keudell, Andrew Branagan, Zachary Hunter, Steven Treon, Shayna Sarosiek, Jorge Castillo

Blood (2025) 146 (Supplement 1): 3577.

https://doi.org/10.1182/blood-2025-3577

Published: 2025

Journal Articles

More than a decade without treatment: Time to first treatment in CLL in a chilean cohort

Macarena Roa, Sofia Pacheco, Claudia Gajardo, Camila Peña, Veronica Lizama, Patricia Graffigna, Ximena Valladares, Jorge Castillo

Blood (2025) 146 (Supplement 1): 7429.

https://doi.org/10.1182/blood-2025-7429

Published: 2025

Journal Articles

Discovery of an undocumented pattern of intron retention that is abundant in healthy B-cells and circumvented in Waldenstrom's macroglobulinemia impacting genes driving cellular growth and survival

Zachary Hunter, Amanda Kofides, Abigail Peachey, Nickolas Tsakmaklis, Maria Luisa Guerrera, Xia Liu, Shirong Liu, Hao Sun, Alberto Guijosa, John Hatcher, Dominic Pizzarella, Christopher Patterson, Andrew Branagan, Shayna Sarosiek, Jorge Castillo, Steven Treon

Blood (2025) 146 (Supplement 1): 3544.

https://doi.org/10.1182/blood-2025-3544

Published: 2025

Journal Articles

Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom's macroglobulinemia.

Blood (2025) 146 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2025-3543

Published: 2025

Journal Articles

Mass spectrometry demonstrates very frequent multi-clonality in familial Waldenström macroglobulinemia and shows distinct IgM profiles across IgM-related disorders.

Alberto Guijosa, Nickolas Tsakmaklis, Abigail Peachey, Nicholas Paciaroni, Nina Budano, Julia Nguyen, Kirsten Meid, Maria Luisa Guerrera, Christopher Patterson, Andrew Branagan, Shayna Sarosiek, Zachary Hunter, Jorge Castillo, Steven Treon

Blood (2025) 146 (Supplement 1): 5392.

https://doi.org/10.1182/blood-2025-5392

Published: 2025

Journal Articles

Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia

Jorge Castillo, Andrew Branagan, Gottfried von Keudell, Alberto Guijosa, Nina Budano, Julia Nguyen, Alexandra Eurell, Kirsten Meid, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Nickolas Tsakmaklis, Zachary Hunter, Steven Treon, Shayna Sarosiek

Blood (2025) 146 (Supplement 1): 1794.

https://doi.org/10.1182/blood-2025-1794

Published: 2025

Journal Articles

LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK

Blood (2025) 146 (Supplement 1): 5731.

https://doi.org/10.1182/blood-2025-5731

Published: 2025

Journal Articles

Zanubrutinib and pirtobrutinib (ZAP) but not ibrutinib and pirtobrutinib (IAP) show synergistic tumor cell killing and suppression of BTK and downstream signaling in MYD88 mutated lymphoma cells.

Dominic Pizzarella, Amanda Kofides, Xia Liu, John Hatcher, Alberto Guijosa, Nickolas Tsakmaklis, Abigail Peachey, Jinhua Wang, Maria Luisa Guerrera, Christopher Patterson, Zachary Hunter, Hao Sun, Shayna Sarosiek, Jorge Castillo, Sara Buhrlage, Sirano Dhe-Paganon, Steven Treon, Shirong Liu

Blood (2025) 146 (Supplement 1): 7453.

https://doi.org/10.1182/blood-2025-7453

Published: 2025

Journal Articles

Baseline clinical characteristics of patients with chronic lymphocytic leukemia (CLL) from 11 Latin American countries: A real-world registry analysis

Ana Oliver, Celso Arrais-Rodrigues, Luis Mario Villela Martinez, Macarena Roa, Sofía Rivarola, Lorena Cardozo, Marialejandra Torres Viera, Denisse Castro, Fabiola Valvert, Daniela Trujillo Loaiza, Anelys García Salgado, Victoria Irigoin, Leila Perobelli, Silvana Cigliari, Alana von Glasenapp, Camila Peña, Sally Paredes, Valeria Buccheri, Virginia Lema Spinelli, Augusto Mirolli, Jose Alvarez, Maura Colturato, Ana Ines Landoni, Gislaine Duarte, Marta Zerga, Sabrina ranero Ferrari, Miguel Pavlovsky, Nancy Cristaldo, Laura Fogliatto, Maria Del Rosario Custidiano, Danielle De Farias, Maria Orlova, Fernando Barroso Duarte, Etelvina Macchiavello, Julio Pose Cabarcos, Sérgio Fortier, Julia Laviano, Clarisa Pagano Vilar, Nelson Hamerschlak, Vera Figueiredo, Fernando Pérez-Jacobo, Javier Retamales, Arianna Robles, German Stemmelin, Rosa Rios Jimenez, Henry Quintero, Brady Beltran, Jorge Castillo, Carlos Chiattone, Luis Malpica

Blood (2025) 146 (Supplement 1): 3908.

https://doi.org/10.1182/blood-2025-3908

Published: 2025

Journal Articles

CD20 (MS4A1) mutations are strongly associated with prior chemoimmunotherapy exposure in Waldenström macroglobulinemia and have predicted functional consequences for the development of CD20-directed cellular therapies.

Alberto Guijosa, Nickolas Tsakmaklis, Sirano Dhe-Paganon, John Hatcher, Andres Ramirez, Dominic Pizzarella, Amanda Kofides, Abigail Peachey, Shirong Liu, Hao Sun, Xia Liu, Maria Luisa Guerrera, Andrew Branagan, Gottfried von Keudell, Shayna Sarosiek, Jorge Castillo, Zachary Hunter, Steven Treon

Blood (2025) 146 (Supplement 1): 3611.

https://doi.org/10.1182/blood-2025-3611

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Frontline therapy patterns and outcomes in chronic lymphocytic leukemia: A real-world, multicenter analysis from Latin America.

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study

Double-hit alterations of TP53 identify ultra high-risk disease in previously treated, MYD88 mutated waldenstrom macroglobulinemia.

Real-world outcomes of primary gastric diffuse large B cell lymphoma in Latin America: A multicenter cohort from the grupo de estudio latinoamericano de linfoproliferativos (GELL)

Comparative effectiveness of R-minichop versus R-CHOP in older patients with diffuse large B-cell lymphoma: A propensity score-matched analysis from a real-world grupo de estudio latinoamericano de linfoproliferativos (GELL) cohort

Machine learning-based immunoinflammatory phenotypes predict survival in Latin American patients with diffuse large B-cell lymphoma: A multicenter cohort study of grupo de estudio latinoamericano de linfoproliferativos (GELL)

Deep responses following treatment with loncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those withhigh-risk, TP53-altered Waldenström macroglobulinemia.

Novel mechanistic insights for IRAK1 and IRAK4 signaling provide a framework for the development of dual IRAK1 and IRAK4 protacs for MYD88 mutated lymphomas.

Prognostic factors and 5-year overall survival in older adults (≥60 years) with Hodgkin lymphoma in Latin America: A multicenter cohort study

Venetoclax or pirtobrutinib in relapsed/refractory Waldenström macroglobulinemia: Clinical and molecular predictors and sequencing implications

More than a decade without treatment: Time to first treatment in CLL in a chilean cohort

Discovery of an undocumented pattern of intron retention that is abundant in healthy B-cells and circumvented in Waldenstrom's macroglobulinemia impacting genes driving cellular growth and survival

Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom's macroglobulinemia.

Mass spectrometry demonstrates very frequent multi-clonality in familial Waldenström macroglobulinemia and shows distinct IgM profiles across IgM-related disorders.

Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia

LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK

Zanubrutinib and pirtobrutinib (ZAP) but not ibrutinib and pirtobrutinib (IAP) show synergistic tumor cell killing and suppression of BTK and downstream signaling in MYD88 mutated lymphoma cells.

Baseline clinical characteristics of patients with chronic lymphocytic leukemia (CLL) from 11 Latin American countries: A real-world registry analysis

CD20 (MS4A1) mutations are strongly associated with prior chemoimmunotherapy exposure in Waldenström macroglobulinemia and have predicted functional consequences for the development of CD20-directed cellular therapies.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only